CA19-9 as a non-invasive marker for disease activity in Hepatitis B patients: is there any role?
The combined elevation of tumor markers carbohydrate antigen 19-9 (CA 19-9) and carbohydrate antigen 125 (CA 125) has been shown to be associated with the severity of liver fibrosis in patients with liver disease. We assessed the association between CA 19-9 and viral hepatitis B activity which wil...
| Main Authors: | , , |
|---|---|
| Format: | Conference or Workshop Item |
| Language: | English |
| Published: |
2010
|
| Subjects: | |
| Online Access: | http://irep.iium.edu.my/23085/ http://irep.iium.edu.my/23085/1/p361.pdf |
| id |
iium-23085 |
|---|---|
| recordtype |
eprints |
| spelling |
iium-230852012-04-09T06:15:21Z http://irep.iium.edu.my/23085/ CA19-9 as a non-invasive marker for disease activity in Hepatitis B patients: is there any role? Nik Ahmad, Nik Nur Fatnoon Hasmoni, Mohamed Hadzri Jaafar, Khairul Azhar R Medicine (General) The combined elevation of tumor markers carbohydrate antigen 19-9 (CA 19-9) and carbohydrate antigen 125 (CA 125) has been shown to be associated with the severity of liver fibrosis in patients with liver disease. We assessed the association between CA 19-9 and viral hepatitis B activity which will allow us to know the usefulness of CA 19-9 as a surrogate marker for the disease activity in hepatitis B patients. Methods: A prospective study involving 60 patients with hepatitis B surface antigen positive carrier was performed. These patients were divided into 2 groups according to HBeAg positivity. Tumor marker CA 19-9 was determined using routine laboratory methods and correlated with the disease activity by measuring hepatitis B viral DNA (HBV DNA) and serum alanine transaminase (ALT) and aspartate transaminase (AST) levels. Results: Eleven (18%) were HBeAg positive and 49 (82%) were HBeAg negative. The mean (standard deviation) age in the former group was 40.7 (11.7) years and in the latter group was 40.8 (12.5) years (p = 0.98). There was no significance difference between the two groups with respect to the levels of serum ALT/AST, HBV DNA and CA 19-9. There was no significant correlation seen between CA 19-9 and serum ALT/AST. It was the same with the levels of HBV DNA. Discussions and conclusion: The use of CA 19-9 as a non-invasive marker for disease activity in patients with hepatitis B infection was not useful. There was no role of CA 19-9 in hepatitis B patients to assess the disease activity. 2010 Conference or Workshop Item PeerReviewed application/pdf en http://irep.iium.edu.my/23085/1/p361.pdf Nik Ahmad, Nik Nur Fatnoon and Hasmoni, Mohamed Hadzri and Jaafar, Khairul Azhar (2010) CA19-9 as a non-invasive marker for disease activity in Hepatitis B patients: is there any role? In: IIUM Research, Innovation & Invention Exhibition (IRIIE 2010), 26 - 27 January 2010, Kuala Lumpur. |
| repository_type |
Digital Repository |
| institution_category |
Local University |
| institution |
International Islamic University Malaysia |
| building |
IIUM Repository |
| collection |
Online Access |
| language |
English |
| topic |
R Medicine (General) |
| spellingShingle |
R Medicine (General) Nik Ahmad, Nik Nur Fatnoon Hasmoni, Mohamed Hadzri Jaafar, Khairul Azhar CA19-9 as a non-invasive marker for disease activity in Hepatitis B patients: is there any role? |
| description |
The combined elevation of tumor markers carbohydrate antigen 19-9 (CA 19-9) and carbohydrate
antigen 125 (CA 125) has been shown to be associated with the severity of liver fibrosis in patients with
liver disease. We assessed the association between CA 19-9 and viral hepatitis B activity which will allow
us to know the usefulness of CA 19-9 as a surrogate marker for the disease activity in hepatitis B patients.
Methods: A prospective study involving 60 patients with hepatitis B surface antigen positive carrier
was performed. These patients were divided into 2 groups according to HBeAg positivity. Tumor marker
CA 19-9 was determined using routine laboratory methods and correlated with the disease activity by
measuring hepatitis B viral DNA (HBV DNA) and serum alanine transaminase (ALT) and aspartate
transaminase (AST) levels.
Results: Eleven (18%) were HBeAg positive and 49 (82%) were HBeAg negative. The mean (standard
deviation) age in the former group was 40.7 (11.7) years and in the latter group was 40.8 (12.5) years (p =
0.98). There was no significance difference between the two groups with respect to the levels of serum
ALT/AST, HBV DNA and CA 19-9. There was no significant correlation seen between CA 19-9 and
serum ALT/AST. It was the same with the levels of HBV DNA.
Discussions and conclusion: The use of CA 19-9 as a non-invasive marker for disease activity in
patients with hepatitis B infection was not useful. There was no role of CA 19-9 in hepatitis B patients to
assess the disease activity. |
| format |
Conference or Workshop Item |
| author |
Nik Ahmad, Nik Nur Fatnoon Hasmoni, Mohamed Hadzri Jaafar, Khairul Azhar |
| author_facet |
Nik Ahmad, Nik Nur Fatnoon Hasmoni, Mohamed Hadzri Jaafar, Khairul Azhar |
| author_sort |
Nik Ahmad, Nik Nur Fatnoon |
| title |
CA19-9 as a non-invasive marker for disease activity in Hepatitis B patients: is there any role? |
| title_short |
CA19-9 as a non-invasive marker for disease activity in Hepatitis B patients: is there any role? |
| title_full |
CA19-9 as a non-invasive marker for disease activity in Hepatitis B patients: is there any role? |
| title_fullStr |
CA19-9 as a non-invasive marker for disease activity in Hepatitis B patients: is there any role? |
| title_full_unstemmed |
CA19-9 as a non-invasive marker for disease activity in Hepatitis B patients: is there any role? |
| title_sort |
ca19-9 as a non-invasive marker for disease activity in hepatitis b patients: is there any role? |
| publishDate |
2010 |
| url |
http://irep.iium.edu.my/23085/ http://irep.iium.edu.my/23085/1/p361.pdf |
| first_indexed |
2023-09-18T20:34:59Z |
| last_indexed |
2023-09-18T20:34:59Z |
| _version_ |
1777408985805094912 |